Rosenfeld Philip J, Moshfeghi Andrew A, Puliafito Carmen A
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Miami, Florida, USA.
Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5.
To determine whether intravitreal bevacizumab could improve optical coherence tomography and visual acuity outcomes in a patient with neovascular age-related macular degeneration who was responding poorly to pegaptanib therapy, an intravitreal injection of bevacizumab (1.0 mg) was given. Within 1 week, optical coherence tomography revealed resolution of the subretinal fluid, resulting in a normal-appearing macular contour. The improved macular appearance was maintained for at least 4 weeks, and visual acuity remained stable. No inflammation was observed. An intravitreal injection of bevacizumab may provide an effective, safe, and inexpensive option for patients with age-related macular degeneration who are losing vision secondary to macular neovascularization.
为了确定玻璃体内注射贝伐单抗能否改善对培加他尼治疗反应不佳的新生血管性年龄相关性黄斑变性患者的光学相干断层扫描结果和视力，给予了一次玻璃体内注射贝伐单抗（1.0毫克）。在1周内，光学相干断层扫描显示视网膜下液消退，黄斑轮廓恢复正常。改善后的黄斑外观维持了至少4周，视力保持稳定。未观察到炎症。对于因黄斑新生血管化而视力下降的年龄相关性黄斑变性患者，玻璃体内注射贝伐单抗可能提供一种有效、安全且廉价的选择。
